VYALEV (Foscarbidopa; Foslevodopa) Patent Expiration, LOE Window & CMS Spending
VYALEV (Foscarbidopa; Foslevodopa) by AbbVie: FDA Orange Book core substance LOE 2035-10-21 (last listed 2040-06-10), 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $2,293 CA SB 17 specialty launch WAC.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | AbbVie |
| FDA Application & Pathway | N216962 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2035-10-21 |
| Last Listed Patent or Exclusivity Date | 2040-06-10 |
| Orange Book Patents (*PED Extensions) | 4 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $0 |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $0 |
| Reported Wholesale Price Change (CA SB 17) | Specialty launch notice ($2,293 intro WAC) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.